MX336830B - Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos. - Google Patents

Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.

Info

Publication number
MX336830B
MX336830B MX2012006347A MX2012006347A MX336830B MX 336830 B MX336830 B MX 336830B MX 2012006347 A MX2012006347 A MX 2012006347A MX 2012006347 A MX2012006347 A MX 2012006347A MX 336830 B MX336830 B MX 336830B
Authority
MX
Mexico
Prior art keywords
chimeric
factor viii
methods
hybrid polypeptides
cells
Prior art date
Application number
MX2012006347A
Other languages
English (en)
Other versions
MX2012006347A (es
Inventor
Alan J Bitonti
Jennifer A Dumont
Susan Low
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Biogen Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Hemophilia Inc filed Critical Biogen Hemophilia Inc
Publication of MX2012006347A publication Critical patent/MX2012006347A/es
Publication of MX336830B publication Critical patent/MX336830B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a uso de un polipéptido del Factor VIII (FVIII) de acción prolongada para la elaboración de un medicamento para reducir la incidencia de un episodio de sangrado en un sujeto humano en necesidad del mismo, en donde el medicamento está adaptado para ser administrable en dosis múltiples a en un intervalo de dosificación de tres días a siete días entre dos dosis, en donde cada una de las dosis múltiples provee de 25 IU/kg A 65 IU/kg del polipéptido del FVIII de acción prolongada, en donde el polipéptido del FVIII de acción prolongada es un híbrido monómero dímero del FVIIIFc que comprende una porción de FVIII y dos porciones de Fc, en donde una de las porciones de Fc se fusiona al extermo C-terminal de la cadena ligera de la porción del FVIII.
MX2012006347A 2009-12-06 2010-12-06 Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos. MX336830B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2012006347A MX2012006347A (es) 2012-10-03
MX336830B true MX336830B (es) 2016-02-03

Family

ID=44115536

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016000039A MX353233B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
MX2012006347A MX336830B (es) 2009-12-06 2010-12-06 Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.
MX2018000089A MX382693B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016000039A MX353233B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018000089A MX382693B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Country Status (30)

Country Link
US (5) US9050318B2 (es)
EP (4) EP3326643B1 (es)
JP (8) JP5903048B2 (es)
KR (1) KR101770849B1 (es)
CN (1) CN102791285A (es)
AU (6) AU2010325787B2 (es)
BR (1) BR112012013502A2 (es)
CA (2) CA2782424C (es)
CO (1) CO6561782A2 (es)
CY (2) CY1119919T1 (es)
DK (1) DK2506868T3 (es)
EA (2) EA025416B1 (es)
ES (2) ES2659888T3 (es)
HR (2) HRP20180135T1 (es)
HU (1) HUE036233T2 (es)
IL (2) IL220204B (es)
LT (1) LT2506868T (es)
ME (1) ME02964B (es)
MX (3) MX353233B (es)
MY (1) MY159135A (es)
NO (1) NO2506868T3 (es)
NZ (2) NZ703153A (es)
PL (2) PL2506868T3 (es)
PT (2) PT3326643T (es)
RS (1) RS56957B1 (es)
SG (3) SG181130A1 (es)
SI (1) SI2506868T1 (es)
SM (1) SMT201800099T1 (es)
WO (1) WO2011069164A2 (es)
ZA (1) ZA201204874B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
JP2013502458A (ja) 2009-08-24 2013-01-24 アムニクス オペレーティング インコーポレイテッド 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
SG181130A1 (en) 2009-12-06 2012-07-30 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT4108671T (lt) 2010-10-01 2025-01-10 Modernatx, Inc. Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
CA2813411C (en) * 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
SI2729161T1 (sl) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc. Himerni in hibridni polipeptidi faktorja III in postopki njihove uporabe
EA028914B1 (ru) * 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
NZ627078A (en) 2012-01-12 2016-07-29 Biogen Ma Inc Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
MX357403B (es) * 2012-01-12 2018-07-09 Bioverativ Therapeutics Inc Polipeptidos de factor viii quimericos y usos de los mismos.
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
BR112014020694A2 (pt) 2012-02-15 2018-05-08 Amunix Operating Inc. proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
CN104427995A (zh) 2012-06-08 2015-03-18 比奥根艾迪克Ma公司 嵌合凝血因子
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
EA201792485A3 (ru) * 2012-07-11 2019-03-29 Амуникс Оперэйтинг Инк. Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты)
EP2877202A4 (en) 2012-07-25 2016-06-01 Biogen Ma Inc BLOOD FACTORY MONITOR TEST AND USES THEREOF
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US10370431B2 (en) 2013-02-15 2019-08-06 Bioverativ Therapeutics Inc. Optimized factor VIII gene
TWI690325B (zh) * 2013-03-15 2020-04-11 美商百歐維拉提夫治療公司 因子viii多肽調配物
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HK1220910A1 (zh) 2013-05-24 2017-05-19 Biogen Ma Inc. 抗-gpiib/iiia抗體或其用途
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
BR112015031856A8 (pt) * 2013-06-20 2022-08-30 Baxalta GmbH Aparelho para prover um regime de dosagem de proteína plasmática terapêutica e dispositivo acessível à máquina
US20160251408A1 (en) * 2013-06-28 2016-09-01 Biogen Ma Inc. Thrombin cleavable linker with xten and its uses thereof
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
EP3027224B1 (en) 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
ES2967617T3 (es) * 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
EP3091997B1 (en) 2014-01-10 2022-07-06 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
KR102567586B1 (ko) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
KR20160145790A (ko) 2014-04-25 2016-12-20 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
EP3411478B1 (en) 2016-02-01 2022-06-08 Bioverativ Therapeutics Inc. Optimized factor viii genes
AU2017250570B2 (en) 2016-04-15 2024-07-25 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
JP7161266B2 (ja) 2016-08-05 2022-10-26 メディミューン，エルエルシー 抗ｏ２抗体およびその使用
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
AU2017346488A1 (en) 2016-10-19 2019-05-30 Humabs Biomed Sa Anti-O1 antibodies and uses thereof
EP3548063A1 (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
KR20260008164A (ko) 2016-12-02 2026-01-15 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
JP2020505424A (ja) 2017-01-31 2020-02-20 バイオベラティブ セラピューティクス インコーポレイテッド 因子ｉｘ融合タンパク質ならびにその製造および使用方法
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
JP7543144B2 (ja) 2018-06-05 2024-09-02 アムジエン・インコーポレーテツド 抗体依存性細胞貪食の調節
CA3110530A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
SG11202105880TA (en) 2018-12-06 2021-07-29 Bioverativ Therapeutics Inc Use of lentiviral vectors expressing factor ix
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
JP7803014B2 (ja) 2019-09-30 2026-01-21 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
IL299333A (en) 2020-06-24 2023-02-01 Bioverativ Therapeutics Inc Methods for the purification of viral vectors
CR20240525A (es) * 2022-04-28 2025-03-05 Biocad Joint Stock Co Ácido nucleico aislado que codifica una proteína de fusión basada en fviii-bdd y en un péptido señal heterólogo, y uso de la misma
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
ATE72838T1 (de) 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
WO1987004187A1 (en) 1986-01-03 1987-07-16 Genetics Institute, Inc. METHOD FOR PRODUCING FACTOR VIII:c-TYPE PROTEINS
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
HUP0303130A2 (hu) * 2001-02-05 2004-01-28 Novo Nordisk Health Care Ag A VII-es faktor és a VIII-as faktor polipeptidek kombinált alkalmazása és ezeket tartalmazó gyógyszerkészítmények
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3002012A1 (en) 2003-05-06 2016-04-06 Biogen Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
WO2005004793A2 (en) * 2003-06-19 2005-01-20 Tanox Inc. Compositions and methods for treating coagulation related disorders
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
MX350293B (es) 2004-11-12 2017-09-04 Bayer Healthcare Llc Modificacion dirigida al sitio del factor viii.
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
ES2476690T3 (es) * 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
WO2010111414A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
SG181130A1 (en) * 2009-12-06 2012-07-30 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
SI2729161T1 (sl) * 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc. Himerni in hibridni polipeptidi faktorja III in postopki njihove uporabe
NZ627078A (en) * 2012-01-12 2016-07-29 Biogen Ma Inc Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
TWI690325B (zh) * 2013-03-15 2020-04-11 美商百歐維拉提夫治療公司 因子viii多肽調配物
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
US20160199455A1 (en) 2016-07-14
JP6385410B2 (ja) 2018-09-05
AU2010325787A2 (en) 2013-06-06
AU2019202969A1 (en) 2019-05-16
AU2021202912B2 (en) 2024-08-01
SG10201907152YA (en) 2019-09-27
NZ600709A (en) 2015-01-30
EP4382170A2 (en) 2024-06-12
IL260769B (en) 2020-03-31
JP2023071969A (ja) 2023-05-23
SG181130A1 (en) 2012-07-30
US9241978B2 (en) 2016-01-26
EP3326643B1 (en) 2021-04-07
US20130274194A1 (en) 2013-10-17
AU2010325787A8 (en) 2012-07-19
BR112012013502A2 (pt) 2017-01-10
AU2017268648B2 (en) 2019-01-31
RS56957B1 (sr) 2018-05-31
MX353233B (es) 2018-01-08
EP2506868B1 (en) 2017-11-15
MX2012006347A (es) 2012-10-03
JP2025083451A (ja) 2025-05-30
HRP20180135T1 (hr) 2018-04-06
EP4382170A3 (en) 2024-09-04
JP2022051964A (ja) 2022-04-01
HRP20211010T1 (hr) 2021-09-17
EA038618B1 (ru) 2021-09-23
US20190262429A1 (en) 2019-08-29
JP5903048B2 (ja) 2016-04-13
HUE036233T2 (hu) 2018-06-28
CY1119919T1 (el) 2018-06-27
IL220204A0 (en) 2012-07-31
AU2021202912A1 (en) 2021-06-03
AU2010325787B2 (en) 2016-05-12
KR101770849B1 (ko) 2017-09-05
SG10201408049SA (en) 2015-02-27
EP3326643A1 (en) 2018-05-30
CN102791285A (zh) 2012-11-21
CO6561782A2 (es) 2012-11-15
MY159135A (en) 2016-12-15
EP2506868A4 (en) 2013-07-24
EA201691109A1 (ru) 2017-01-30
US20220265780A1 (en) 2022-08-25
SMT201800099T1 (it) 2018-03-08
JP6641340B2 (ja) 2020-02-05
JP2020019821A (ja) 2020-02-06
PL2506868T3 (pl) 2018-06-29
NZ703153A (en) 2015-02-27
NO2506868T3 (es) 2018-04-14
US9050318B2 (en) 2015-06-09
AU2017268648A1 (en) 2017-12-21
EA201290443A1 (ru) 2013-06-28
AU2024227757A1 (en) 2024-11-21
DK2506868T3 (da) 2018-01-29
ES2880038T3 (es) 2021-11-23
ES2659888T3 (es) 2018-03-19
WO2011069164A3 (en) 2011-07-28
CY1124888T1 (el) 2023-01-05
SI2506868T1 (en) 2018-04-30
HK1253887A1 (en) 2019-07-05
LT2506868T (lt) 2018-02-26
US20130108629A1 (en) 2013-05-02
AU2016213822B2 (en) 2017-08-31
CA2782424C (en) 2021-07-27
EP3906937A1 (en) 2021-11-10
PT3326643T (pt) 2021-07-12
ZA201204874B (en) 2016-06-29
KR20120129882A (ko) 2012-11-28
PT2506868T (pt) 2018-02-23
CA3121739A1 (en) 2011-06-09
CA2782424A1 (en) 2011-06-09
US11266720B2 (en) 2022-03-08
ME02964B (me) 2018-07-20
MX382693B (es) 2025-03-13
PL3326643T3 (pl) 2021-10-25
JP2017025098A (ja) 2017-02-02
EP2506868A2 (en) 2012-10-10
JP2015083608A (ja) 2015-04-30
AU2016213822A1 (en) 2016-09-01
JP6062459B2 (ja) 2017-01-18
JP2013512678A (ja) 2013-04-18
EA025416B1 (ru) 2016-12-30
WO2011069164A2 (en) 2011-06-09
IL220204B (en) 2018-08-30
JP7244688B2 (ja) 2023-03-22
AU2010325787A1 (en) 2012-07-12
JP2018024706A (ja) 2018-02-15

Similar Documents

Publication Publication Date Title
MY159135A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
MX2020009702A (es) Polipeptidos de factor ix y metodos para usarlos.
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
PH12018501839A1 (en) St2l antagonists and methods of use
HK1213521A1 (zh) Fix多肽的應用
MX2012007710A (es) Alfa-amilasas.
PH12012500862B1 (en) Il-17a antagonists
MX2011012623A (es) Construcciones de casb7439.
GB0818080D0 (en) Immunogenic peptides
HK1185266A (zh) 因子ix多肽及其使用方法
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors

Legal Events

Date Code Title Description
FG Grant or registration